Literature DB >> 3018201

Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.

A Ramos-Gabatin, J A Orzel, T R Maloney, J E Murnane, R D Borchert.   

Abstract

We describe a severe systemic reaction which occurred in a patient on two occasions after i.v. injection of chemically related diphosphonate bone imaging agents. Skin testing showed reactivity to multiple commercially available diphosphonate compounds but no significant response to pyrophosphates. A subsequent pyrophosphate bone scan resulted in no adverse reaction. Severe systemic reactions to diphosphonates can occur, skin testing may prove useful in evaluating allergic reactions, and pyrophosphates appear to be a safe alternative agent in patients proven or suspected allergic to diphosphonates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018201

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Long-lasting dermatological lesions after tiludronate therapy.

Authors:  C Roux; V Listrat; B Villette; M Lessana-Leibowitch; D Ethgen; C Pelissier; M Dougados; B Amor
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

2.  Erythroderma related to the administration of 99mTc-sestamibi: the first report.

Authors:  Spyridoula Doukaki; Mario Aricò; Maria Rita Bongiorno
Journal:  J Nucl Cardiol       Date:  2010-06       Impact factor: 5.952

3.  Severe reaction to diphosphonate: implications for treatment of Paget's disease.

Authors:  A T Elliott; T Murray; R M Mackie; J A Hunter
Journal:  BMJ       Date:  1988-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.